AR112801A1 - CXCR-2 INHIBITORS TO TREAT DISORDERS - Google Patents
CXCR-2 INHIBITORS TO TREAT DISORDERSInfo
- Publication number
- AR112801A1 AR112801A1 ARP180102592A ARP180102592A AR112801A1 AR 112801 A1 AR112801 A1 AR 112801A1 AR P180102592 A ARP180102592 A AR P180102592A AR P180102592 A ARP180102592 A AR P180102592A AR 112801 A1 AR112801 A1 AR 112801A1
- Authority
- AR
- Argentina
- Prior art keywords
- pharmaceutically acceptable
- acceptable salt
- cxcr
- colchicine
- activity
- Prior art date
Links
- 102100028989 C-X-C chemokine receptor type 2 Human genes 0.000 title abstract 3
- 101710082498 C-X-C chemokine receptor type 2 Proteins 0.000 title abstract 3
- 239000003112 inhibitor Substances 0.000 title abstract 3
- IAKHMKGGTNLKSZ-INIZCTEOSA-N (S)-colchicine Chemical compound C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC IAKHMKGGTNLKSZ-INIZCTEOSA-N 0.000 abstract 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 4
- 150000003839 salts Chemical class 0.000 abstract 4
- 229960001338 colchicine Drugs 0.000 abstract 3
- 201000010099 disease Diseases 0.000 abstract 3
- 230000000694 effects Effects 0.000 abstract 3
- 102000000589 Interleukin-1 Human genes 0.000 abstract 2
- 108010002352 Interleukin-1 Proteins 0.000 abstract 2
- 102000003896 Myeloperoxidases Human genes 0.000 abstract 2
- 108090000235 Myeloperoxidases Proteins 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 102000009410 Chemokine receptor Human genes 0.000 abstract 1
- 108050000299 Chemokine receptor Proteins 0.000 abstract 1
- 102000019034 Chemokines Human genes 0.000 abstract 1
- 108010012236 Chemokines Proteins 0.000 abstract 1
- 230000009286 beneficial effect Effects 0.000 abstract 1
- 229940125904 compound 1 Drugs 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- UCCNQCNIPRKLRP-CJNGLKHVSA-N n-[6-[(2r,3s)-3,4-dihydroxybutan-2-yl]oxy-2-[(4-fluorophenyl)methylsulfanyl]pyrimidin-4-yl]-3-methylazetidine-1-sulfonamide Chemical compound N=1C(SCC=2C=CC(F)=CC=2)=NC(O[C@H](C)[C@@H](O)CO)=CC=1NS(=O)(=O)N1CC(C)C1 UCCNQCNIPRKLRP-CJNGLKHVSA-N 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
- C07F5/02—Boron compounds
- C07F5/025—Boronic and borinic acid compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C201/00—Preparation of esters of nitric or nitrous acid or of compounds containing nitro or nitroso groups bound to a carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
N-(6-(((2R,3S)-3,4-dihidroxibutan-2-il)oxi)-2-((4-fluorobencil)tio)pirimidin-4-il)-3-metilazetidina-1-sulfonamida (compuesto 1), un conocido modulador de quimioquinas, en combinación con colchicina es útil en el tratamiento de enfermedades / afecciones en las cuales la modulación de la actividad de los receptores de quimioquinas, la actividad de la interleuquina-1 (IL-1) y/o la actividad de la mieloperoxidasa (MPO) es beneficiosa. En particular, en la presente, se proveen composiciones y métodos para el tratamiento y la prevención de dichas enfermedades / afecciones. Reivindicación 1: Un método para tratar o prevenir una enfermedad o un trastorno en un sujeto, caracterizado porque comprende administrar al sujeto una combinación de: (i) colchicina, o una sal farmacéuticamente aceptable de la misma; y (ii) un inhibidor de CXCR-2, o una sal farmacéuticamente aceptable del mismo. Reivindicación 31: Una composición farmacéutica caracterizada porque comprende i) colchicina, o una sal farmacéuticamente aceptable de la misma; ii) un inhibidor de CXCR-2, o una sal farmacéuticamente aceptable del mismo; y iii) un excipiente farmacéuticamente aceptable.N- (6 - (((2R, 3S) -3,4-dihydroxybutan-2-yl) oxy) -2 - ((4-fluorobenzyl) thio) pyrimidin-4-yl) -3-methylazetidine-1-sulfonamide (compound 1), a known chemokine modulator, in combination with colchicine is useful in the treatment of diseases / conditions in which modulation of chemokine receptor activity, interleukin-1 (IL-1) activity and / or myeloperoxidase (MPO) activity is beneficial. In particular, herein are provided compositions and methods for the treatment and prevention of such diseases / conditions. Claim 1: A method for treating or preventing a disease or disorder in a subject, characterized in that it comprises administering to the subject a combination of: (i) colchicine, or a pharmaceutically acceptable salt thereof; and (ii) a CXCR-2 inhibitor, or a pharmaceutically acceptable salt thereof. Claim 31: A pharmaceutical composition characterized in that it comprises i) colchicine, or a pharmaceutically acceptable salt thereof; ii) a CXCR-2 inhibitor, or a pharmaceutically acceptable salt thereof; and iii) a pharmaceutically acceptable excipient.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US15/702,693 US20180221312A1 (en) | 2016-03-11 | 2017-09-12 | Cxcr-2 inhibitors for treating disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR112801A1 true AR112801A1 (en) | 2019-12-11 |
Family
ID=65723077
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP180102592A AR112801A1 (en) | 2017-09-12 | 2018-09-12 | CXCR-2 INHIBITORS TO TREAT DISORDERS |
Country Status (11)
| Country | Link |
|---|---|
| EP (1) | EP3681861A4 (en) |
| JP (1) | JP2020533332A (en) |
| CN (1) | CN111356675A (en) |
| AR (1) | AR112801A1 (en) |
| AU (1) | AU2018334152A1 (en) |
| BR (1) | BR112020004697A2 (en) |
| CA (1) | CA3075305A1 (en) |
| CO (1) | CO2020003061A2 (en) |
| MX (2) | MX2020002754A (en) |
| TW (1) | TW201919599A (en) |
| WO (1) | WO2019055509A1 (en) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113893252A (en) | 2016-03-11 | 2022-01-07 | 阿迪亚生命科学公司 | CXCR-2 inhibitors for the treatment of crystalline joint disorders |
| US20220404373A1 (en) * | 2019-09-25 | 2022-12-22 | The Board Of Trustees Of The Leland Stanford Junior University | Methods for diagnosing and treating uveitis |
| WO2021089715A1 (en) * | 2019-11-06 | 2021-05-14 | Murray And Poole Enterprises, Ltd. | Use of colchicine in the treatment and prevention of lung cancer |
| JP2023501584A (en) * | 2019-11-13 | 2023-01-18 | ラプト・セラピューティクス・インコーポレイテッド | Crystal Forms of C—C Chemokine Receptor Type 4 Antagonists and Uses Thereof |
| US20230210792A1 (en) * | 2020-06-05 | 2023-07-06 | Aristea Therapeutics, Inc. | Use of a combination of colchicine and a cxcr-2 inhibitors for the treatment or prevention of familial mediterranean fever (fmf) and flare-ups thereof |
| TWI774059B (en) * | 2020-09-14 | 2022-08-11 | 國立陽明大學 | Use of cxcl5 neutralizing antibody in the manufacture of a medicament for preventing or treating peripheral arterial occlusive disease |
| TW202227081A (en) * | 2020-09-15 | 2022-07-16 | 美商雅力思提雅治療公司 | Compositions and methods for the treatment of palmoplantar pustulosis |
| JP2023543248A (en) * | 2020-09-24 | 2023-10-13 | ▲広▼州▲輯▼因医▲療▼科技有限公司 | Use of compounds to improve human hematopoietic stem cell transplantation efficiency |
| CN115385865B (en) * | 2022-06-29 | 2023-06-16 | 深圳大学 | Small molecule inhibitor with CXCR2 inhibition activity and preparation method and application thereof |
| CN117503740A (en) * | 2023-11-09 | 2024-02-06 | 复旦大学 | BACH1 inhibitor and application thereof |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2007519751A (en) * | 2004-01-30 | 2007-07-19 | シェーリング コーポレイション | CXC-Chemokine receptor ligand crystal polymorph |
| US8298533B2 (en) * | 2008-11-07 | 2012-10-30 | Medimmune Limited | Antibodies to IL-1R1 |
| CU24292B1 (en) * | 2011-07-12 | 2017-12-08 | Astrazeneca Ab | N- (6 - ((2R, 3S) - 3,4- DIHYDROXIBUTAN-2-ILOXI) -2- (4-FLUOROBENCILTI) PIRIMIDIN-4-IL) -3- METHYLACETIDINE-1-SULPHONAMIDE AS A CHEMIOCINE RECEPTOR MODULATOR |
| CN113893252A (en) * | 2016-03-11 | 2022-01-07 | 阿迪亚生命科学公司 | CXCR-2 inhibitors for the treatment of crystalline joint disorders |
-
2018
- 2018-09-12 AU AU2018334152A patent/AU2018334152A1/en not_active Abandoned
- 2018-09-12 MX MX2020002754A patent/MX2020002754A/en unknown
- 2018-09-12 WO PCT/US2018/050656 patent/WO2019055509A1/en unknown
- 2018-09-12 AR ARP180102592A patent/AR112801A1/en unknown
- 2018-09-12 TW TW107132083A patent/TW201919599A/en unknown
- 2018-09-12 BR BR112020004697-3A patent/BR112020004697A2/en unknown
- 2018-09-12 CN CN201880073230.7A patent/CN111356675A/en active Pending
- 2018-09-12 EP EP18856459.5A patent/EP3681861A4/en not_active Withdrawn
- 2018-09-12 JP JP2020514219A patent/JP2020533332A/en active Pending
- 2018-09-12 CA CA3075305A patent/CA3075305A1/en active Pending
-
2020
- 2020-03-11 MX MX2022014868A patent/MX2022014868A/en unknown
- 2020-03-16 CO CONC2020/0003061A patent/CO2020003061A2/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MX2020002754A (en) | 2020-07-20 |
| JP2020533332A (en) | 2020-11-19 |
| WO2019055509A1 (en) | 2019-03-21 |
| EP3681861A1 (en) | 2020-07-22 |
| EP3681861A4 (en) | 2021-06-09 |
| CN111356675A (en) | 2020-06-30 |
| CA3075305A1 (en) | 2019-03-21 |
| MX2022014868A (en) | 2022-12-15 |
| AU2018334152A1 (en) | 2020-04-23 |
| TW201919599A (en) | 2019-06-01 |
| BR112020004697A2 (en) | 2020-10-27 |
| CO2020003061A2 (en) | 2020-06-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR112801A1 (en) | CXCR-2 INHIBITORS TO TREAT DISORDERS | |
| EA202090955A1 (en) | METHODS OF USING EHMT2 INHIBITORS IN TREATMENT OR PREVENTION OF BLOOD DISORDERS | |
| CL2020002146A1 (en) | N- (phenyl) -2- (phenyl) pyrimidine-4-carboxamide derivatives and related compounds as hpki inhibitors to treat cancer. | |
| CL2021001292A1 (en) | Combination therapy including a krasg12c inhibitor and one or more additional pharmaceutically active agents for the treatment of cancers | |
| CL2017002481A1 (en) | Combination therapy of fibroblast growth factor receptor (fgfr) / progamed death 1 (pd 1) for cancer treatment | |
| CO2019015090A2 (en) | Treatment methods for cystic fibrosis | |
| UY38613A (en) | PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND METHODS OF USE OF THE SAME | |
| AR085662A1 (en) | METHODS AND COMPOSITIONS TO TREAT HYPERURICEMIA AND METABOLIC DISORDERS ASSOCIATED WITH HYPERURICEMIA | |
| NI201100147A (en) | METHODS TO TREAT ACUTE MYOCARDIAL INFARCTIONS AND RELATED DISORDERS. | |
| CO2020013600A2 (en) | Treatment of hidradenitis suppurativa using jak inhibitors | |
| EA201790406A1 (en) | KINURENIN-3-MONOXYGENASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND METHODS OF THEIR USE | |
| AR090601A1 (en) | QUINURENINE-3-MONOOXIGENASA INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND METHODS OF THE SAME USE | |
| BR112018068393A2 (en) | cxcr-2 inhibitors for the treatment of crystal arthropathy disorders | |
| BR112014004587A2 (en) | synergistic combinations of pi3k- and mek inhibitors | |
| CL2020002465A1 (en) | Fibrotic disease treatment method | |
| CL2021000030A1 (en) | Use of sgc stimulators for the treatment of mitochondrial disorders | |
| PE20230180A1 (en) | USE OF BI853520 IN CANCER TREATMENT | |
| CO2019004004A2 (en) | Pharmaceutical composition and method for the treatment of non-alcoholic fatty liver disease | |
| CL2022000875A1 (en) | Complement factor d inhibitors for oral administration | |
| AR124449A1 (en) | SOS1 INHIBITORS AND USES THEREOF | |
| CO2022005926A2 (en) | Complement factor d inhibitors for oral administration | |
| PH12020551179A1 (en) | Methods for treating mitochondrial disorder | |
| DOP2023000060A (en) | LINE-1 INHIBITORS TO TREAT DISEASES BACKGROUND OF THE INVENTION | |
| CO2023014650A2 (en) | Dosage and administration of recombinant l-asparaginase | |
| BR112015012497A2 (en) | pharmaceutical combinations |